pharma · Advanced or metastatic solid tumors · Waldenström's Macroglobulinemia
BeiGene
BeiGene clinical programs — 14 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- 55 Cambridge Parkway, Suite 700W, Cambridge, MA 02142, US
- Founded
- 2010
- Employees
- 2,047
- Programs
- 14
- Drugs
- 19
- Patents
- 25
BeiGene projects
14 ClinicalTrials.gov programs sponsored by BeiGene.
BeiGene has 14 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
BGB-3111
BeiGene
Waldenström's Macroglobulinemia
1 trial -
BGB-A317-A1217-302
BeiGene
Locally advanced, unresectable, or metastatic non small cell lung cancer
1 trial -
Pamiparib capsule
BeiGene
Ovarian Cancer
1 trial -
Tislelizumab
BeiGene
Recurrent or Metastatic Nasopharyngeal Cancer
1 trial -
Tislelizumab
BeiGene
Non-small Cell Lung Cancer
2 trials -
Zanubrutinib
BeiGene
B-cell Malignancies
2 trials -
Zanubrutinib
BeiGene
Chronic Lymphocytic Leukemia
1 trial -
OBINUTUZUMAB, Zanubrutinib
BeiGene
Relapsed/Refractory Follicular Lymphoma
1 trial -
Sitravatinib
BeiGene
Carcinoma, Hepatocellular
1 trial -
Surzebiclimab
BeiGene
Locally Advanced or Metastatic Solid Tumors for Phase 1, Dose Escalation and Phase 2 Safety Lead-in
1 trial -
Tislelizumab
BeiGene
Cervical Cancer
1 trial -
BGB DXP593
BeiGene
Covid19
1 trial -
BGB-21447-101
BeiGene
mature B-Cell malignancies
1 trial -
BGB-A317-A3055-101
BeiGene
Advanced or metastatic solid tumors
1 trial
Frequently asked questions
How many clinical projects does BeiGene have?
14 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.